Prognostic Factors in Survival Free of Progression After Androgen Deprivation Therapy for Treatment of Prostate Cancer-Reference-Cited by-同舟云学术

Prognostic Factors in Survival Free of Progression After Androgen Deprivation Therapy for Treatment of Prostate Cancer

Published:1989-05 Issue:5 Volume:141 Page:1139-1142
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Ishikawa Satoru¹,Soloway Mark S.¹,Van Der Zwaag Roger¹,Todd Barbara¹

Affiliation:

1. From the Department of Urology, University of Tennessee, Memphis Veterans Administration Hospital and Department of Health Services Research, Baptist Memorial Hospital, Memphis, Tennessee

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference13 articles.

1. Carcinoma of the prostate: metastases, therapy and survival; a statistical analysis of five hundred cases;McCrea;J. Int. Coll. Surg.,1958

2. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan;Soloway;Cancer,1988

3. Leuprolide versus diethylstilbestrol for metastatic prostate cancer;New Engl. J. Med.,1984

4. Treatment of advanced cancer of the prostate;Chisholm;Sem. Surg. Oncol.,1985

5. Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological Group

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis;Current Opinion in Urology;2023-09-25

2. The Role of Long Non-Coding RNAs in Epithelial-Mesenchymal Transition-Related Signaling Pathways in Prostate Cancer;Frontiers in Molecular Biosciences;2022-07-18

3. The value of bone scans to predict survival time in patients with diagnosed prostate cancer: single-center retrospective study;Journal of Radiology and Oncology;2022-05-25

4. Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer;Cancers;2021-08-05

5. RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer;The Prostate;2020-05-25